Bringing the fundamentals into focus…
Back to AnaptysBio, Inc.
How AnaptysBio, Inc. stacks up
ANAB · against 454 other Healthcare companies of similar size
Valuation
83/ 100
Near the top of its peers.
Ranked #85 of 455 · scores higher than 80% of peers
Bars: peers in each 10-point band of the valuation score62 peers with a valuation score of 80–89, including ANAB · Click a bar to see the companies
Why valuation scores 83?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- lower earnings for the price paid: weaker than 67% of peers. Earnings yield: 13.7% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 4.3% vs peer median 4.0%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.3% vs peer median 0.0%
Metric by metric
Position: dot = ANAB, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ANAB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 444 reported | -2.0% | 1.5% | 33% | 30% | |
| EBITDA yieldHigher is better · 458 reported | 4.3% | 4.5% | 48% | 50% | |
| Free cash flow yieldHigher is better · 208 reported | 0.3% | -0.9% | 55% | 20% | |
| Book yieldHigher is better · 448 reported | 0.7% | 40.2% | 5% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ANABScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score